Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk communication strategy

This article was originally published in The Tan Sheet

Executive Summary

FDA says the Risk Communication Advisory Committee will discuss the draft strategic plan and offer further advice on priorities for research on effective risk communication in a meeting scheduled for April 30 and May 1. At its previous meeting, the committee emphasized the need for FDA to assess the effectiveness of its communications as a part of ensuring safe and effective use of medical products (1"The Tan Sheet" Sept. 1, 2008, p. 8)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts